Hector Alila, D.V.M., Ph.D.
Venture Partner for Industry Diligence
Ferran Prat, Ph.D., J.D.
Senior Vice President
Research Administration and Industry Relations
Shara Avis Pecoraro, M.H.A.
Strategic Industry Ventures
Scientific Advisory Committee
Philip Jones, Ph.D.
Head of Drug Discovery (IACS) MD Anderson Cancer Center
Timothy Yap, MBBS, Ph.D., FRCP
Dept. of Investigational Cancer Therapeutics, Division of Cancer Medicine
Other MD Anderson Members
Christopher Flowers, M.D.
Department Chair, Department of Lymphoma/Myeloma, Division of Cancer Medicine
Jason Bock, Ph.D.
VP and Head of Biologics Product Development
Jeffrey J. Molldrem, M.D
Dept. of Stem Cell Transplantation and Cellular Therapy, Division of Cancer
Albert C. Koong, M.D., Ph.D., FACR, FASTRO
Dept. of Radiation Oncology (Clinical)
Amir Anthony Jazaeri, M.D.
Dept. of Gynecologic Oncology and Reproductive Medicine, Division of Surgery
Jianjun Gao, M.D., Ph.D.
Dept. of Genitourinary Medical Oncology, Division of Cancer Medicine
Navel G. Daver M.D.
Dept. of Leukemia, Division of Cancer Medicine
Scott Kopetz, M.D., Ph.D., FACP
Dept. of Gastrointestinal Medical Oncology, Division of Cancer Medicine
Ochsner Health System and LSUHSC-Shreveport
Marc Matrana, M.D.
Medical Director, Precision Cancer Therapies (Phase I) Research Program for Ochsner
Sarah Thayer, M.D., Ph.D., FACS
Director of Feist Weiller Cancer Center
University of Texas Member Consultant
S. Gail Eckhardt, M.D., FASCO
Associate Dean of Cancer Programs, Livestrong Cancer Institutes
Mikael Dolsten, MD, PhD
Pfizer – EVP
Worldwide Research & Development
Axel Hoos, MD, PhD
GlaxoSmithKline – SVP
TA Head of Oncology R&D and Head of Immuno-Oncology
Ridgeback Biotherapeutics and Ridgeback Diagnostics
CEO and Co-Founder
Iron Park Capital
Richard van den Broek
Wayne Holman, MD